We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok ✕
The unique environment of microgravity may offer timeline and cost reduction benefits throughout the drug development process. Space-based biopharma research allows for higher quality protein structures for drug design in preclinical development. Coupling target validation with the more predictive disease models created in microgravity can contribute to lower failure rates in the clinic, reducing overall clinical development costs. Space is also being used as a domain to investigate ultra-sensitive, targeted methods for diagnostic and therapeutic technology development.